{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=24", "query": { "intervention": "dose level 1", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 29101, "total_pages": 2911, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T01:35:18.714Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00309842", "title": "Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Myelofibrosis", "MDS", "Refractory Anemia", "Chronic Lymphocytic Leukemia", "Prolymphocytic Leukemia", "Non-Hodgkin's Lymphoma", "Leukemia", "Lymphoma", "Multiple Myeloma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 213, "start_date": "2005-07-28", "completion_date": "2019-11-22", "has_results": true, "last_update_posted_date": "2020-09-10", "last_synced_at": "2026-11-14T01:35:18.714Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Seattle, Washington", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00309842" }, { "nct_id": "NCT02778386", "title": "Evaluating the Safety and Plasma Levels of N-Methanocarbathymidine (N-MCT) in Normal Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Toxicity" ], "interventions": [ { "name": "N-Methanocarbathymidine", "type": "DRUG" }, { "name": "Placebo Capsule", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "N&N Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 28, "start_date": "2016-04", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2016-09-22", "last_synced_at": "2026-11-14T01:35:18.714Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02778386" }, { "nct_id": "NCT06942741", "title": "A Study to Evaluate the Effect of Formulation and Food on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-011)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Calderasib OCT", "type": "DRUG" }, { "name": "Calderasib FCT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 52, "start_date": "2025-05-13", "completion_date": "2025-08-04", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-11-14T01:35:18.714Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06942741" }, { "nct_id": "NCT00044005", "title": "Safety and Tolerability Study of Drug to Treat Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Lurasidone 20 mg", "type": "DRUG" }, { "name": "Lurasidone 40 mg", "type": "DRUG" }, { "name": "Lurasidone 80mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 98, "start_date": "2002-09", "completion_date": "2003-11", "has_results": true, "last_update_posted_date": "2014-04-17", "last_synced_at": "2026-11-14T01:35:18.714Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Cerritos, California • Garden Grove, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cerritos", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044005" }, { "nct_id": "NCT05540860", "title": "A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "Sevasemten Dose 1", "type": "DRUG" }, { "name": "Sevasemten Dose 2", "type": "DRUG" }, { "name": "Sevasemten Dose 3", "type": "DRUG" }, { "name": "Sevasemten Dose 4", "type": "DRUG" }, { "name": "Sevasemten Dose 5", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Edgewise Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "9 Years", "sex": "MALE", "summary": "4 Years to 9 Years · Male only" }, "enrollment_count": 76, "start_date": "2022-10-24", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-11-14T01:35:18.714Z", "location_count": 14, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 11 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05540860" }, { "nct_id": "NCT01218620", "title": "Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm" ], "interventions": [ { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" }, { "name": "Midazolam Hydrochloride", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Tolbutamide", "type": "DRUG" }, { "name": "Dextromethorphan Hydrobromide", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2010-09", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-11-14T01:35:18.714Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01218620" }, { "nct_id": "NCT03495882", "title": "A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Zalifrelimab", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2017-12-18", "completion_date": "2022-07-15", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-11-14T01:35:18.714Z", "location_count": 13, "location_summary": "Goodyear, Arizona • Duarte, California • Miami, Florida + 10 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03495882" }, { "nct_id": "NCT04349124", "title": "Persistent Postpartum Hypertension Pilot Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypertension in Pregnancy" ], "interventions": [ { "name": "Nifedipine Extended-Release Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "18 Years to 60 Years · Female only" }, "enrollment_count": 12, "start_date": "2020-08-25", "completion_date": "2021-03-04", "has_results": true, "last_update_posted_date": "2023-04-03", "last_synced_at": "2026-11-14T01:35:18.714Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04349124" }, { "nct_id": "NCT07015996", "title": "Efficacy of Tezepelumab in Peanut Oral Immunotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peanut Allergy" ], "interventions": [ { "name": "Tezepelumab", "type": "BIOLOGICAL" }, { "name": "Peanut Oral Immunotherapy (OIT)", "type": "DRUG" }, { "name": "Placebo for Tezepelumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "12 Years to 55 Years" }, "enrollment_count": 62, "start_date": "2026-07-27", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-11-14T01:35:18.714Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Baltimore, Maryland + 6 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07015996" }, { "nct_id": "NCT03812562", "title": "Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Yttrium Y 90 Glass Microspheres", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2019-02-07", "completion_date": "2023-10-19", "has_results": false, "last_update_posted_date": "2024-02-21", "last_synced_at": "2026-11-14T01:35:18.714Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03812562" } ] }